Akers Biosciences Signs US Distribution Agreement With Typenex
June 04 2014 - 2:00AM
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR), a leading designer
and manufacturer of rapid diagnostic screening and testing
products, announces that the Company has entered into a sales and
distribution agreement for the US, that can be renewed after one
year by mutual consent (the "Agreement"), with Typenex Medical, LLC
("Typenex") of Chicago, Illinois for the Company's PIFA Heparin/PF4
and PIFA PLUSS PF4 rapid tests ("PIFA Heparin Tests").
The Agreement marks a shift in the Company's strategy to
accelerate sales of its two signature PIFA Heparin Tests to
hospitals. The PIFA Heparin Tests are designed to rapidly assist in
the diagnosis of Heparin-Induced Thrombocytopenia ("HIT"): a life-
and limb-threatening condition that is analogous to an allergy to
the blood thinner, Heparin. To date, ABI's revenues for the PIFA
Heparin Tests have been generated by a distribution network
comprising the top two distributors in the US hospital market,
supported by a small technical sales force employed by the Company.
Typenex, a product development and sales organization, has a team
of twelve sales executives with a proven sales model that is
focused on established relationships with a customer base of 2,000
hospitals across the US to which they directly market blood typing
and transfusion safety products. Given the synergies between ABI's
and Typenex's target markets, Typenex will act as ABI's sales
agents marketing directly to potential PIFA Heparin Test customers
thereby increasing the Company's potential distribution network.
ABI's account executives will function as technical specialists
assisting new clients in the adoption of the Company's PIFA Heparin
Tests.
In addition, the PIFA Heparin Tests will continue to be
distributed by both Cardinal Health and Fisher HealthCare in the
US.
"Typenex will be implementing a sales strategy for these
flagship tests which highlights not only the compelling
cost-reduction case but also the wider substantial benefits of
factoring timely diagnosis of HIT into hospital risk management
protocol," said Raymond F. Akers Jr., Ph.D, Executive Chairman. "By
incorporating ABI's test into risk management protocol, the
hospital pharmacy gains a drug management tool that helps it
contain the use of expensive – and sometimes problematic –
alternatives to Heparin to a much smaller, targeted patient
population," explained Dr. Akers. "By positioning ABI's rapid tests
as a value creator, the company believes that uptake of these PIFA
Heparin products can be greatly enhanced," he added.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics. Additional
information on the Company and its products can be found at
www.akersbiosciences.com.
Follow us on Twitter: @AkersBio
ABOUT TYPENEX
Typenex is a medical processes support company for hospitals and
clinical personnel concerned with delivering processes that
streamline healthcare. www.typenex.com
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Akers Biosciences, Inc.
Tel. +1 856 848 8698
Twitter. @AkersBio
Jon Cunningham
RedChip Companies, Inc. (US Investor Relations)
Tel. +1 407 644 4256 x107
Emma Earl / Harrison Clarke
Daniel Stewart (Nomad and Broker)
Tel. +44 (0)20 7776 6550
Ben Simons / Alexandra Roper
Vigo Communications (UK Investor Relations)
Tel. +44 (0)20 7016 9570
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024